[ad_1]
Anuj Virmani, Managing Director – India, Johnson & Johnson MedTech
Johnson & Johnson MedTech has partnered with Qure.ai for the early detection of lung cancer in India.
The collaboration aims to identify lung cancer at its most treatable stage, according to a note on the development. The initiative is part of Project BreatheEZ, a joint effort between Qure.ai and Johnson & Johnson MedTech, designed to establish AI-led Incidental Pulmonary Nodule (IPN) Detection Clinics across leading hospitals in India.
Anuj Virmani, Managing Director – India, Johnson & Johnson MedTech, said in a statement: “Lung cancer continues to be one of the leading causes of cancer-related deaths in both men and women. In India, where access to advanced healthcare facilities is often limited, especially in tier-2 and tier-3 cities, patients face significant challenges in receiving timely and effective diagnoses, which further delays access to treatment.”
The note further stated that the collaboration will help screen and flag suspicious nodules in X-rays and CT scans that could potentially be malignant.
Published on May 9, 2025
[ad_2]
Source link
